Where was DSIP-like material most abundant?

Stomach, at 849 pg/mg, against a low of 86 pg/mg in muscle across the 12 areas examined.

Was it actually DSIP?

Chromatography showed the immunoreactive material was mostly larger than DSIP, so predominantly not the nine-residue peptide.

What did trypsin digestion show?

It produced small immunoreactive peptides with minimal loss of immunoreactivity — consistent with the epitope sitting inside larger molecules.

DSIP (Delta Sleep-Inducing Peptide)

What the Antibody Found in Peripheral Tissue

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Graf and Kastin reported DSIP-like material across 12 rat tissue areas by radioimmunoassay, ranging from 86 pg/mg in muscle to 849 pg/mg in stomach. Chromatography then showed the immunoreactive material was mostly larger than DSIP itself.

Key facts

Study: Graf & Kastin 1984 (PMID 6548030)
Journal: Proc Soc Exp Biol Med, October 1984
Tissues examined: 12 areas
Lowest: 86 pg/mg — muscle
Highest: 849 pg/mg — stomach
Chromatography result: Material mostly larger than DSIP
After trypsin: Small immunoreactive peptides appeared

What the study set out to do

DSIP had been reported in brain by radioimmunoassay and immunocytochemistry. Graf and Kastin extended the measurement to peripheral tissue, extracting 12 areas with water and quantifying immunoreactive material in each. Asking whether a supposedly brain-associated peptide appears elsewhere is a reasonable and useful question.

The distribution they found

Immunoreactive material in every area, from 86 pg/mg in muscle to 849 pg/mg in stomach — roughly a tenfold range, with the highest reading in the gastrointestinal tract. For a peptide named after an effect on sleep, the stomach being the richest source is not what the name would lead anyone to expect.

Research material referenced

DSIP 5mg — third-party HPLC tested

View — £13.99

The chromatography, which is the important part

They ran the material on Sephadex G-15 and G-25 columns, which separate by size. The immunoreactive material appeared mostly larger than DSIP. So whatever the antibody was binding in these tissues was predominantly not the nine-residue peptide — it was bigger molecules carrying a region the antibody recognised.

What the trypsin experiment adds

Digesting the material with trypsin produced small immunoreactive peptides with only minimal reduction in immunoreactivity. That is consistent with the epitope being contained inside larger molecules and released by cleavage — which is a coherent explanation, and also means the original signal was not measuring free peptide.

Why the title says what it says

The paper is titled DSIP-like material exists in peripheral organs of rats in large dissociable forms. Every element of that is doing work: DSIP-like rather than DSIP, material rather than peptide, and large dissociable forms describing what was actually found. The authors reported the complication rather than burying it.

How this bears on the wider literature

Distribution data is often cited as evidence that an endogenous peptide is real and functionally placed. Where that data comes from immunoassay and the immunoreactive material turns out to be mostly something larger, the inference weakens considerably. This is one reason a fifty-year literature has not consolidated, and it was visible in the primary work from the beginning.

Quick reference

Observation	What it shows
Immunoreactivity in 12 tissues	The antibody bound something everywhere
Highest in stomach, 849 pg/mg	Not a brain-restricted distribution
Mostly larger by chromatography	Most of it was not DSIP
Trypsin releases small fragments	Epitope sits inside larger molecules

Extended research context

The DSIP (Delta Sleep-Inducing Peptide) deep dive

Deep dive: a name that was a hypothesis, not a finding

In 1977 the Schoenenberger-Monnier group in Basel electrically stimulated the thalamus of a sleeping rabbit, collected blood draining from its brain, isolated a peptide fraction, and reported that administering it into the ventricles of awake rabbits produced delta-wave EEG activity. They named it delta sleep-inducing peptide. By the standards of the time this was careful, imaginative work, and they followed it properly - the 1978 Pflugers Archiv paper reported sequence, synthesis and activity of the synthetic nonapeptide rather than stopping at a suggestive fraction. The problem is not the original research. It is that a name recording a hypothesis has been read ever since as a summary of established pharmacology, and almost nobody checks whether it was earned.

Deep dive: the three things that are missing

A proposed endogenous peptide becomes accepted biology by a recognisable route. The gene is located. The precursor protein is characterised. A receptor is identified, giving a mechanism and a testable target. DSIP has completed none of these in nearly fifty years. The receptor gap is the most disabling - without one there is no mechanism to test, no dose-response to build, no antagonist to design, and no way to establish that an observed effect runs through the proposed pathway at all. The gene gap is the hardest to explain away: modern genomics located MOTS-c inside a short open reading frame nested within the mitochondrial 12S rRNA gene, sequence already annotated as something else. That a peptide described in 1977 still has no identified gene in any genome is a substantive observation, not an accident of effort.

Deep dive: why 519 papers is not 519 confirmations

DSIP has roughly 519 indexed PubMed records - more than Selank's 135 or Semax's 231. Publication volume tracks how interesting a question is, not how well it has been answered. A tractable question generates a burst of work and then stops; a question that resists resolution generates papers indefinitely, each a further attempt rather than a further confirmation. Kovalzon's 2006 review in the Journal of Neurochemistry states the field's own assessment in its title: a still unresolved riddle. Reading any individual DSIP paper without that context invites mistaking activity for consensus.

Research applications

▸Historical study of humoral sleep-factor hypotheses
▸Electroencephalography and delta-wave research methodology
▸Structure-activity work on flexible, acidic short peptides
▸Comparative work on peptides lacking identified receptors
▸Analytical method development for tryptophan-containing peptides

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Protect from prolonged light — the single tryptophan is mildly photosensitive
✓Expect pH-dependent solubility; the peptide is strongly acidic with no basic residue
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating the name as evidence of the effect

Fix: The name records a 1977 hypothesis from a single rabbit EEG study. It is not a summary of established pharmacology.

✗ Citing the 1977 paper as proof DSIP induces sleep

Fix: It reports delta-wave EEG activity in rabbits after intraventricular administration — a narrower claim than inducing sleep, in one species, by a route that bypasses every normal barrier.

✗ Assuming DSIP is an established endogenous human peptide

Fix: No gene has been identified in any species, no precursor characterised and no receptor found.

✗ Reading 519 papers as 519 confirmations

Fix: Volume reflects an unresolved question attracting sustained attempts, not accumulated confirmation.

✗ Making any sleep claim about supplied material

Fix: The evidence does not support it and a therapeutic claim about research material is what MHRA enforcement targets.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Where was DSIP-like material most abundant?: Stomach, at 849 pg/mg, against a low of 86 pg/mg in muscle across the 12 areas examined.
Was it actually DSIP?: Chromatography showed the immunoreactive material was mostly larger than DSIP, so predominantly not the nine-residue peptide.
What did trypsin digestion show?: It produced small immunoreactive peptides with minimal loss of immunoreactivity — consistent with the epitope sitting inside larger molecules.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More DSIP (Delta Sleep-Inducing Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum